{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 1 anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 2 anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 1 bloating"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 2 constipation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 2 diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 1 nausea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 1 chills"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 2 fever"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 1 non-cardiac chest pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 1 night sweats"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 2 sinusitis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 1 lymphocyte count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 2 lymphocyte count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 2 weight loss"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 1 hypercalcemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 3 hypercalcemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 1 hyponatremia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 1 arthralgia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 3 paresthesia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 1 productive cough"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 2 post nasal drip"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 1 hyperhidrosis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 1 pruritus"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 1 hypertension"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"-The severity of AEs will be graded by the investigator according to the CTCAE, Version 4.03","groups":[{"description":"-MEDI4736 will be given to all patients \\> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \\< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.","id":"OG000","title":"Cohort A: Non-small Cell Lung Cancer w/o Corticosteroids"},{"description":"-MEDI4736 will be given to all patients \\> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \\< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.","id":"OG001","title":"Cohort B: Epithelial Origin Solid Tumors w/o Corticosteroids"},{"description":"-MEDI4736 will be given to all patients \\> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \\< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.","id":"OG002","title":"Cohort C: NSCLC or Non-NSCLC w/Corticosteroids"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"There were not any participants enrolled in Cohort B or Cohort C.","reportingStatus":"POSTED","timeFrame":"30 days after completion of treatment (estimated to be 7 months)","title":"Safety of MEDI4736 in Advanced Solid Epithelial-derived Tumor Patients With Brain Metastases as Measured by Number of Participants With Treatment-emergent Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}